Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Investing Activities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Cash from Investing Activities for 6 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 45.67% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $109.4 million, a 307.88% increase, with the full-year FY2025 number at $109.4 million, up 307.88% from a year prior.
  • Cash from Investing Activities was $14.8 million for Q4 2025 at TScan Therapeutics, down from $32.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $48.4 million in Q2 2025 to a low of -$82.4 million in Q3 2024.
  • A 5-year average of -$908300.0 and a median of -$684500.0 in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 14384.43% in 2023, then soared 4415.39% in 2024.
  • TScan Therapeutics' Cash from Investing Activities stood at -$2.2 million in 2021, then skyrocketed by 37.72% to -$1.4 million in 2022, then skyrocketed by 238.93% to $1.9 million in 2023, then surged by 1326.71% to $27.3 million in 2024, then crashed by 45.67% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Cash from Investing Activities are $14.8 million (Q4 2025), $32.6 million (Q3 2025), and $48.4 million (Q2 2025).